3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
132
Myelodysplastic Syndromes
57
Leukemia
32
Leukemia, Myelomonocytic, Chronic
23
Recurrence
18
Lymphoma, Large B-Cell, Diffuse
10
Myeloproliferative Disorders
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Neoplasms
8
Congenital Abnormalities
7
Primary Myelofibrosis
6
Melanoma
6
Hodgkin Disease
6
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
5
Ovarian Neoplasms
5
Blast Crisis
5
Thrombocythemia, Essential
4
Polycythemia Vera
4
Myelodysplastic-Myeloproliferative Diseases
4
Lymphoma
4
Leukemia, Monocytic, Acute
4
Leukemia, Biphenotypic, Acute
4
Anemia, Refractory, with Excess of Blasts
4
Neoplasm Metastasis
3
Leukemia, Myelomonocytic, Acute
3
Leukemia, Myeloid, Accelerated Phase
3
Head and Neck Neoplasms
3
Fallopian Tube Neoplasms
3
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Interventions
spartalizumab
1
sapropterin
1
penpulimab
1
niraparib
1
anlotinib
1
Taxes
1
Ipilimumab
1
IFL protocol
1
Gemcitabine
1
Decitabine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Pancreatic Adenocarcinoma Metastatic
×
Decitabine
×
Clear all
NCT05360264
2025-03-24
ORIENTATE
Regina Elena Cancer Institute
Phase 2
Terminated
7 enrolled